JW Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
323
- Stock Symbol
-
02126
- Share Price
-
$0.25
- (As of Thursday Closing)
JW Therapeutics General Information
Description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Contact Information
Website
www.jwtherapeutics.comCorporate Office
- Building B, 5/F, Wison Center
- 666 Haike Road, Pudong New Area
- Shanghai, 200131
- China
Corporate Office
- Building B, 5/F, Wison Center
- 666 Haike Road, Pudong New Area
- Shanghai, 200131
- China
JW Therapeutics Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.25 | $0.24 | $0.15 - $0.45 | $103M | 414M | 918K | -$0.21 |
JW Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 7,067 | (2,569) | 20,480 | 376,948 |
| Revenue | 24,030 | 24,574 | 21,635 | 4,769 |
| EBITDA | (88,355) | (97,496) | (114,159) | (102,168) |
| Net Income | (87,245) | (108,553) | (125,641) | (108,769) |
| Total Assets | 272,391 | 302,753 | 404,584 | 488,948 |
| Total Debt | 52,355 | 44,973 | 40,457 | 23,068 |
JW Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
JW Therapeutics Comparisons
Industry
Financing
Details
JW Therapeutics Competitors (55)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Gamida Cell | Formerly VC-backed | Boston, MA | ||||
| CureVac | Formerly VC-backed | Tubingen, Germany | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Agenus | Formerly VC-backed | Lexington, MA |
JW Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
JW Therapeutics Executive Team (5)
| Name | Title | Board Seat |
|---|---|---|
| Min Liu | Chief Executive Officer & Executive Director | |
| Yiping Li MD | Chief Executive Officer & Chairman | |
| Shaun Cordoba | Chief Scientific Officer | |
| Wenjun Sun | Vice President, Business Development & Governmental Affairs |
JW Therapeutics Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Cheng Liu Ph.D | Self | Board Member | |
| Edward Hu Ph.D | WuXi AppTec | Board Member | |
| Hans Bishop | Juno Therapeutics | Board Member | |
| Krishnan Viswanadhan | Self | Board Member | |
| Steven Harr MD | Juno Therapeutics | Board Member |
JW Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
JW Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
JW Therapeutics ESG
Risk Overview
Risk Rating
Updated September, 01, 2022
30.41 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,708
Rank
Percentile
Pharmaceuticals
Industry
of 884
Rank
Percentile
Biotechnology
Subindustry
of 399
Rank
Percentile
JW Therapeutics FAQs
-
When was JW Therapeutics founded?
JW Therapeutics was founded in 2016.
-
Who is the founder of JW Therapeutics?
Yiping Li MD is the founder of JW Therapeutics.
-
Who is the CEO of JW Therapeutics?
Min Liu and Yiping Li MD are the CEOs of JW Therapeutics.
-
Where is JW Therapeutics headquartered?
JW Therapeutics is headquartered in Shanghai, China.
-
What is the size of JW Therapeutics?
JW Therapeutics has 323 total employees.
-
What industry is JW Therapeutics in?
JW Therapeutics’s primary industry is Biotechnology.
-
Is JW Therapeutics a private or public company?
JW Therapeutics is a Public company.
-
What is JW Therapeutics’s stock symbol?
The ticker symbol for JW Therapeutics is 02126.
-
What is the current stock price of JW Therapeutics?
As of 10-Oct-2024 the stock price of JW Therapeutics is $0.25.
-
What is the current market cap of JW Therapeutics?
The current market capitalization of JW Therapeutics is $103M.
-
What is JW Therapeutics’s current revenue?
The trailing twelve month revenue for JW Therapeutics is $24M.
-
Who are JW Therapeutics’s competitors?
NexImmune, Gamida Cell, CureVac, Kite Pharma, and Agenus are some of the 55 competitors of JW Therapeutics.
-
What is JW Therapeutics’s annual earnings per share (EPS)?
JW Therapeutics’s EPS for 12 months was -$0.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
